Annual Progress Reports
>
2024-25 Annual Report
>
Finances

Finances

Financial presentation based on MRA’s 2024 externally audited financials. Full audit and IRS 990 available at curemelanoma.org/financials

Statement of Financial Position

Assets
Total 2024
Total 2023
Cash and Cash Equivalents
$10,318,419
$10,055,472
Investments
$12,173,429
$11,779,185
Contributions Receivable (Net)
$2,317,764
$2,538,036
Prepaid Expenses & Other Assets
$383,197
$165,962
Total Assets
$25,192,749
$24,538,655
Liabilities
Total 2024
Total 2023
Accounts Payable
$250,042
$184,366
Grants Payable (Net)
$12,726,845
$10,848,720
Deferred Revenue
$442,019
$497,500
Total Liabilities
$13,418,906
$11,530,586
Net Assets
Total 2024
Total 2023
Unrestricted
$9,456,079
$10,470,033
Temporarily Unrestricted
$2,317,764
$2,538,036
Total Net Assets
$11,773,843
$13,008,069
Total Liabilities & Net Assets
$25,192,749
$24,538,655

Statement of Activities

Revenue
Total 2024
Total 2023
Contributions (Collectible Net)
$11,051,580
$4,920,205
Special Events (Net)
$3,678,561
$2,806,338
Sponsorship
$787,500
$651,705
Interest/Investment
$772,519
$1,334,327
In Kind Contributions
$112,666
$210,864
Write-Off
$(343,032)
$(170,150)
Other Income (Loss)
$89,824
$7,826
Total Revenues
$16,149,618
$9,761,115
Expenses
Total 2024
Total 2023
Research Grants
$13,209,814
$6,702,128
Personnel Costs
$1,954,058
$1,963,354
Travel & Entertainment
$449,212
$503,582
Other Expenses
$494,704
$562,391
Meetings & Conferences
$449,619
$415,778
Professional Fees
$677,578
$356,784
Occupancy
$148,859
$101,844
Total Expenses
$17,383,844
$10,605,861
NET INCOME/(LOSS)
$(1,234,226)
$(844,746)

Total 2024 Program Costs

$17,383,844
Research Grants  $13,209,814  76%
Scientific Program Non-Grant Expenses  $2,178,814  12%
Fundraising  $803,958  5%
Management & Admin  $629,363  4%
Patient Engagement  $561,978  3%
Annual Report Content
Share on social